Platelet transfusion is a necessary life sustaining therapy for extreme thrombocytopenia from multiple etiologies. However, refractoriness develops in some patients such that transfused platelets are rapidly cleared, and refractory patients are at risk for catastrophic hemorrhage. One cause of refractoriness is humoral immunization to MHC-I alloantigens. However, approximately 50% of patients with alloantibodies to MHC-I do not become refractory. The factors that determine whether an alloimmunized patient is refractory remain undefined. Both mice and humans encode four distinct IgG subclasses, each with different effector function characteristics. In this report we forward the hypothesis that IgG subclass composition of alloantisera affects refractoriness. A novel panel of mice was generated with mutated effector function for different murine IgG subclasses. Elimination of effector function of IgG2c (but not IgG1 or IgG2b) eliminated the ability of alloantisera to clear transfused platelets. Together, these data demonstrate the differential platelet clearing activity of distinct IgG subclasses in vivo and support the hypothesis that differences in IgG subclass affect whether alloimmunization results in refractoriness to platelet transfusion.
Frost et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: